Cabrera OA

Language: Spanish
References: 20
Page: 37-41
PDF size: 378.17 Kb.

ABSTRACT

Pioderma gangrenosum (PG) is an uncommon ulcerative cutaneous dermatosis associated with a variety of systemic diseases, including inflammatory bowel disease (IBD), arthritis, leukaemia, hepatitis, and primary billiary cirrhosis. Other cutaneous ulceration resembling PG had been described in literature. The legs are most commonly affected but other parts of the skin and mucous membranes may also be involved.
Diagnosis of PG is based on history of an underlying disease, typical clinical presentation, histopathology, and exclusion of other diseases that would lead to a similar appearance. Treatment consists of local and systemic approaches. Systemic steroids are generally used first. If the lesions are refractory, steroids are combined with other immunosuppressive therapy or to antimicrobial agents.

REFERENCES

1. Abu-Elmagd K, Van Thiel DH, Jegasothy BV, et al. Resolution of severe pyoderma gangrenosum in patient with streakin leukocyte factor disease after treatement with Tacrlimus (FK 506) . Ann Intern Med 1993; 119: 595-598.

2. Armstrong PM, Ilyas I, Pandey R, Berendt AR, et al. Pyoderma gangrenosum. A diagnosis not to be miseed. J Bone Joint Surg (Br) 1999; 81-B: 893-894.

3. Bhat RM. Management of pyoderma gangrenosum-An update. Indian J Dermatol Venerreol Leprol 2004; 70: 329-335.

4. Blitz NM, Rudikoff D. Pyoderma gangrenosum. Mt Sinai J Med 2001; 68: 287-297.

5. Brooklin TN, Dunnill MGS, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomized, double blind, placebo controlled trial. Gut 2006; 55: 505-509.

6. Callen JP. Pyoderma gangrenosum. Lancet 1998; 351: 581-585.

7. Ehling A, Karrer S, Klebl F, et al. Therapeutic management of pyoderma gangrenosum. Arthritis & Rheumatism 2004; 50 (10): 3076-3084.

8. Daniels NH, Callen JP. Mycophenolate mofetil is a effective treatment for peristomal pyoderma gangrenosum. Arch Dermatol 2004; 140: 1427-1429.

9. Hughes AP, Jackson JM, Callen JP. Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA 2000; 284: 1546-1548.

10. Krüger S, Piroth W, Takji BA, et al. Multiple aseptic pulmonary nodules with central necrosis in association with pyoderma gangrenosum. Chest 2001; 119: 977-978.

11. Laurencin CT, Shoen SL. Pyoderma gangrenosum affecting the hand. J Bone Joint Surg (Br) 1994; 76-B: 985-986.

12. Lear JT, Atherton MT, Byrne JPH. Neutrophilic dermatoes: pyoderma gangrenosum and Sweet´s syndrome. Postgrad Med J 1997; 73: 65-68.

13. López San Román A, Bermejo I, Aldanondo I, et al. Pioderma gangrenoso asociado a colitis ulcerosa: respuesta a infliximab. Rev Esp Enferm Dig 2004; 96(6): 420-424.

14. Nousari HC, Lynch W, Anhalt GJ, et al. The effectiveness of mycophenolate mofetil in refractory pyoderma gangrenosum. Arch Dermatol 1998; 134: 1509-1511.

15. Spangler JG. Pyoderma gangrenosum in patient with psoriatic arthritits. JABFP 2001; 14 (6): 466-469.

16. Rozin AP, Balbir-Gurman A, Gilead L, Slodownik. Combined therapy for pyo-derma gangrenosum. Ann Rheuma Dis 2004; 63: 888-889.

17. Sentamilselvi G, Manoharan K, Saraswath D, Janaki VR. Pyoderma gangrenosum-variants and associations. Indian J Dermatol 2002; 47(4): 230-233.

18. Tan MH, Gordon M, Lebwohl O, et al. Improvement of pyoderma gangrenosum and psoriasis associated Crohn disease with anti-tumor necrosis factor α monoclonal antibody. Arch Dermatol 2001; 137: 930-933.

19. Trost LB, McDonnell JK. Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J 2005; 81: 580-585.

20. Wollina U. Pyoderma gangrenosum -a review. Orphanet Journal of Rare Disease 2007; 2:19. En: http://www.OJRD.com/conten/2/1/19